Saghmos Therapeutics' is developing ST-62516 to prevent cardiorenal complications of contrast-induced acute kidney injury. We are poised to initiate a Phase 3 study for ST-62516 in 2021.
Contrast-induced acute kidney injury is a multi-billion dollar market opportunity, with no pharmacological agents approved to prevent or treat it.
Contrast-induced acute kidney injury is a multi-billion dollar market opportunity, with no pharmacological agents approved to prevent or treat it.
Company Type:
Company Website:
Company HQ State:
Connecticut
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
ST-62516
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
